Is BPC-157 legal in the US and the EU?

Can a pharmacy compound BPC-157 in the US right now?

As of October 2026, one narrow path is open. On 28 October 2026 HHS said it does not intend to take enforcement action against some compounders of BPC-157 acetate¹¹. The compounder must be a state-licensed pharmacy, a federal facility or a licensed physician, and ten conditions must be met¹¹. They include a patient's prescription, an ingredient from an FDA-registered maker with a certificate of analysis, and one active ingredient per product¹¹. Compounding pharmacies otherwise work under a separate pathway from full drug approval, which needs a bulk substance to meet an applicable pharmacopoeia monograph and come from an FDA-registered facility⁴.

This is a promise about enforcement. It does not change the law, and it does not put BPC-157 on the FDA's compounding list. The policy runs until the FDA decides BPC-157 in a final rule, and HHS may revisit it if a safety signal or product quality issue appears¹¹. Leaving the FDA's safety-risk list on 22 April 2026 did not by itself make BPC-157 eligible^1,11. FDA's May 2026 briefing document found the evidence weighs against placing either BPC-157 form on the list². The advisory committee then voted 8 to 6 to recommend it, by most published accounts, against its own staff's assessment^3,10.

Is BPC-157 a scheduled controlled substance in the US?

No. A search of the DEA's current list of controlled substances, the August 2026 edition, found no mention of BPC-157 or its chemical name anywhere in the text⁶. This is a distinct legal question from FDA approval status.

A substance can be uncontrolled by the DEA and still be an unapproved new drug under FDA law at the same time, which is BPC-157's position. Its absence from the DEA's list has no bearing on whether a company can lawfully manufacture, market, or sell it for human use.

What is BPC-157's status under EU medicines law?

There is no EU-level authorisation and no registered EU clinical activity for BPC-157 at all. A search of the EU Clinical Trials Register returned zero matching trials as of 17 September 2026⁷. A search of the European Medicines Agency's published assessment reports, the formal record of centrally authorised medicines, located no entry for BPC-157⁸.

This is a no-record-found result rather than an explicit EU statement that the substance is prohibited. The EU medicines framework generally has nothing to say about a substance until someone files for authorisation or registers a trial involving it, and no one has done either for BPC-157 at the EU level as of this date.

Does selling BPC-157 as 'research use only' change its legal status in either jurisdiction?

No. FDA's own regulations define intended use by objective evidence, including labelling claims, advertising, and other statements, not by the label alone⁵. A seller who markets BPC-157 for human therapeutic effects while stamping it research use only has not changed its legal category; the FDA's 2026 warning letters to peptide sellers over exactly this pattern confirm this is an active enforcement position, not a theoretical point.

The EU's medicinal-product framework works the same way: what a product is called does not decide what rules apply to it, its actual intended use does.

Is BPC-157's legal status the same as its status in competitive sport?

No, and this is a genuinely separate framework worth naming so it is not confused with drug law. The World Anti-Doping Agency's 2026 Prohibited List bans any substance with no current approval by a governmental regulatory health authority for human therapeutic use under category S0, at all times, and names BPC-157 as an example⁹.

This ban applies to athletes under the WADA code. It holds regardless of what any single country's drug scheduling or compounding law says, and regardless of the HHS compounding policy of October 2026. An athlete cannot rely on that policy or a later rule to make BPC-157 permissible in competition. The WADA ban is triggered by the same underlying fact, lack of approval for human therapeutic use, that also blocks FDA approval and EU authorisation.

What would change this answer

An FDA final rule on the 503A bulks list would be the single biggest change to this answer. It would end the HHS interim policy for BPC-157. HHS narrowing or withdrawing that policy would change the compounding section. A filed EU marketing authorisation application or a newly registered EU clinical trial would change the EU section. Any DEA scheduling action would change the controlled-substance section, though nothing in the current record suggests one is under consideration.